According to WIRED, fatty liver disease now affects approximately 30 percent of adults worldwide, and more than a billion people carry liver fat exceeding 5 to 10 percent of the organ's total weight. The condition typically develops without noticeable symptoms and is rarely detected at an early stage — WIRED reported that three-quarters of people with cirrhosis or advanced scarring are only diagnosed once the disease has become life-threatening.
The Hidden Epidemic
Fatty liver disease causes inflammation, cell damage, and the formation of scar tissue known as fibrosis, according to WIRED. Progressive fat accumulation can lead to liver failure and has been linked to an increased risk of cardiovascular disease and various cancers. Because symptoms are rare, early diagnosis is uncommon even among high-risk groups such as people with obesity and type 2 diabetes, WIRED reported.
Jeffrey Lazarus, a professor at the CUNY Graduate School of Public Health and Health Policy, told WIRED that AI tools could be used to comb through electronic health records and pinpoint the people most likely to have accrued worrying amounts of liver fat. He described a system that works retrospectively at scale:
AI can retrospectively go through massive numbers of hospital visits and lab reports, says Lazarus. You can use that to really prioritize who’s at most risk.
The Screening Gap
Simple, noninvasive means of assessing liver health exist but are rarely used, even in people known to be at higher risk, WIRED reported. The Fib-4 index, for example, rates a person’s risk of advanced liver fibrosis by computing a score between 0 and 6 based on age, levels of two liver enzymes, and blood-clotting ability. Doctors also have access to a more accurate second-line blood test called the enhanced liver fibrosis test, which measures levels of two proteins involved in creating scar tissue and an enzyme that inhibits scar clearance.
WIRED reported that using both tests in patients with worrying amounts of liver fat improved diagnosis of advanced fibrosis by four-fold. However, physicians already facing a growing workload and administrative burden do not see adding more testing as sustainable.
| Test | What it measures | Role in screening |
|---|---|---|
| Fib-4 index | Age, two liver enzyme levels, blood-clotting ability | Produces a 0–6 risk score for advanced liver fibrosis |
| Enhanced liver fibrosis test | Two proteins involved in scar formation plus an enzyme that inhibits scar clearance | More accurate second-line blood test |
| Combined use | — | Improved advanced-fibrosis diagnosis four-fold, per WIRED |
AI as a Background Worker
Jonathan Dranoff, a professor of medicine at Yale University, told WIRED that any new tool must be easy to integrate: "You have to have something that can run in the background or it’s easy to just hit a button and do it."
Dranoff and Lazarus both foresee a role for AI in taking existing data from routine blood testing and automating the calculation of Fib-4 scores, making it easier for primary care physicians to identify the right patients to refer, according to WIRED. This would use data already collected during annual checkups — no new tests or extra manual steps for clinicians.
Early Intervention Can Reverse Damage
If fatty liver disease is identified early, much of the damage is highly reversible, WIRED reported. In the initial stages, lifestyle changes such as reducing alcohol intake, losing weight through dietary improvements and exercise, and even drinking more coffee have all been shown to reverse scarring and inflammation. For people with moderate to advanced liver scarring, novel treatments including the GLP-1 medication semaglutide and a drug called resmetirom have been shown to be highly effective therapeutics, according to WIRED.
Lazarus pointed out that the liver can regenerate and fibrosis can be reversed, but medicine has traditionally focused on late-stage care: "trying to see how long we can keep a patient alive rather than finding them early and preventing the condition from advancing."
What This Means for Enterprise Technology Leaders
WIRED reported that growing numbers of specialists are investigating how AI might help get ahead of fatty liver disease. The proposal from Lazarus and Dranoff is to automate Fib-4 scoring from routine blood test data already sitting in electronic health records. For technology leaders evaluating AI deployments, the use case shows the value of tools that run in the background, using existing data streams to produce decision-ready outputs without adding manual work — a design principle articulated directly by the clinicians in the WIRED report.
Sources:
